LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Accueil・Liste d'Actions・Xencor Inc

Xencor Inc

Fermé

SecteurSoins de santé

11.24 -5.15

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.2

Max

11.44

Chiffres clés
By Trading Economics
Revenu	-214M -129M
Ventes	-24M 4.5M
BPA	-1.71
Marge bénéficiaire	-2,854.65
Employés	260
EBITDA	-81M -75M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+131.73% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-42M 948M
Ouverture précédente	16.39
Clôture précédente	11.24

Sentiment de l'Actualité

By Acuity

34%

66%

69 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

7.87 / 10.84 Support & Résistance

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 mai 2026, 23:53 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Acquisitions, Fusions, Rachats

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Acquisitions, Fusions, Rachats

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Acquisitions, Fusions, Rachats

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Acquisitions, Fusions, Rachats

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Acquisitions, Fusions, Rachats

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

131.73% hausse

Prévisions sur 12 Mois

Moyen 26 USD 131.73%

Haut 43 USD

Bas 13 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

69 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.